GlassScriptPhysician profile
Retty George
NPI 1326613688
$880.60
in general payments reported to CMS, 2019-2025
15 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $200 · 2024: $274 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.60 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $95.18 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $91.61 | 2023-2025 | Farxiga, Airsupra |
| Amgen INC. | $90.25 | 2022-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $80.62 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.01 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $68.14 | 2022-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $49.45 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $48.25 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $44.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.53 | 2024-2025 | |
| Phadia US INC. | $25.83 | 2025 | Immunocap |
| Dexcom, INC. | $24.28 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $24.03 | 2025 | Intellis Adaptivestim |
| Bausch Health US, LLC | $18.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Retty George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.